Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 6/20 | 0.37 |
| ▸ | FPR2 | P25090 | 6/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21723726 | 0.87 | TERT (0.39) | TERTAAK1 | |
| SCHEMBL23037527 | 0.83 | KDM4E (0.42) | KDM4EPOLBEGFRRAF1KDR | |
| SCHEMBL21723968 | 0.75 | EHMT2 (0.40) | EGFR | |
| SCHEMBL23037489 | 0.73 | EGFR (0.51) | EGFRRAF1KDRMAP2K2MAP2K1 | |
| SCHEMBL12471807 | 0.72 | EPHX1 (0.44) | GBA1EPHX1KDM4EPOLBCYP3A4 | |
| SCHEMBL12472645 | 0.72 | EPHX1 (0.38) | GBA1EPHX1FPR3FPR2CYP3A4 | |
| SCHEMBL1230928 | 0.71 | LATS1 (0.43) | FPR3FPR2EGFRRAF1KDR | |
| SCHEMBL26554119 | 0.71 | CA1 (0.46) | KDM4EPOLBFPR3FPR2AAK1 | |
| SCHEMBL26554150 | 0.71 | AAK1 (0.47) | KDM4EPOLBFPR3FPR2AAK1 | |
| SCHEMBL203808 | 0.70 | STK17B (0.44) | FPR3FPR2EGFRRAF1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3837015-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3837015-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112996567-A | Imidazo [4,5-C ] quinoline-derived NLRP 3-modulators | 先天肿瘤免疫公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | GBA1 2745/4885EPHX1 2530/4885KDM4E 3888/4885 |
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | GBA1 2745/4885EPHX1 2530/4885KDM4E 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.